EP0974584A4 - Composes a anneaux condenses, leur procede de production et leur utilisation - Google Patents

Composes a anneaux condenses, leur procede de production et leur utilisation

Info

Publication number
EP0974584A4
EP0974584A4 EP98904386A EP98904386A EP0974584A4 EP 0974584 A4 EP0974584 A4 EP 0974584A4 EP 98904386 A EP98904386 A EP 98904386A EP 98904386 A EP98904386 A EP 98904386A EP 0974584 A4 EP0974584 A4 EP 0974584A4
Authority
EP
European Patent Office
Prior art keywords
substituted
group
producing
same
fused ring
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP98904386A
Other languages
German (de)
English (en)
Other versions
EP0974584A1 (fr
EP0974584B1 (fr
Inventor
Tetsuya Aono
Fumio Itoh
Tomohiro Kaku
Masuo Yamaoka
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Publication of EP0974584A1 publication Critical patent/EP0974584A1/fr
Publication of EP0974584A4 publication Critical patent/EP0974584A4/fr
Application granted granted Critical
Publication of EP0974584B1 publication Critical patent/EP0974584B1/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/06—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom
    • C07D213/16—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom containing only one pyridine ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Vaporization, Distillation, Condensation, Sublimation, And Cold Traps (AREA)
EP98904386A 1997-02-21 1998-02-19 Composes a anneaux condenses, leur procede de production et leur utilisation Expired - Lifetime EP0974584B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP3792797 1997-02-21
JP3792797 1997-02-21
PCT/JP1998/000688 WO1998037070A1 (fr) 1997-02-21 1998-02-19 Composes a anneaux condenses, leur procede de production et leur utilisation

Publications (3)

Publication Number Publication Date
EP0974584A1 EP0974584A1 (fr) 2000-01-26
EP0974584A4 true EP0974584A4 (fr) 2000-05-17
EP0974584B1 EP0974584B1 (fr) 2003-01-15

Family

ID=12511197

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98904386A Expired - Lifetime EP0974584B1 (fr) 1997-02-21 1998-02-19 Composes a anneaux condenses, leur procede de production et leur utilisation

Country Status (8)

Country Link
US (1) US6420375B1 (fr)
EP (1) EP0974584B1 (fr)
CN (1) CN1251577A (fr)
AT (1) ATE231128T1 (fr)
AU (1) AU6229698A (fr)
CA (1) CA2281598A1 (fr)
DE (1) DE69810760T2 (fr)
WO (1) WO1998037070A1 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW407153B (en) * 1997-10-27 2000-10-01 Nippon Kayaku Kk Imidazole compounds and their use
WO2000039716A2 (fr) * 1998-12-23 2000-07-06 Astrazeneca Ab Composes chimiques
DE60045474D1 (de) 1999-01-13 2011-02-17 Univ New York State Res Found Neues verfahren zum erschaffen von proteinkinase-inhibitoren
US6417366B2 (en) 1999-06-24 2002-07-09 Abbott Laboratories Preparation of quinoline-substituted carbonate and carbamate derivatives
US6552078B2 (en) 1999-10-27 2003-04-22 Nobex Corp 6-methoxy-2-naphthylacetic acid prodrugs
US6436990B1 (en) 1999-10-27 2002-08-20 Nobex Corporation 6-methoxy-2-naphthylacetic acid prodrugs
TWI262791B (en) * 1999-10-27 2006-10-01 Nobex Corp 6-methoxy-2-naphthylacetic acid prodrugs
CN100572363C (zh) 2000-11-17 2009-12-23 武田药品工业株式会社 咪唑衍生物、其制备方法及其用途
US6960586B2 (en) 2000-11-20 2005-11-01 Takeda Pharmaceutical Company Limited Imidazole derivatives, process for their preparation and their use
CA2431171A1 (fr) 2000-12-08 2002-06-13 Takeda Chemical Industries, Ltd. Derives thiazole substitues porteurs de groupes 3-pyridyl, procede d'elaboration et leur utilisation
US7005445B2 (en) 2001-10-22 2006-02-28 The Research Foundation Of State University Of New York Protein kinase and phosphatase inhibitors and methods for designing them
CA2464214C (fr) * 2001-10-22 2011-02-08 The Research Foundation Of State University Of New York Inhibiteurs de proteines kinases et de proteines phosphatases, methodes d'identification et methodes d'utilisation associees
AU2003229142A1 (en) * 2002-06-07 2003-12-22 Cortical Pty Ltd Naphthalene derivatives which inhibit the cytokine or biological activity of macrophage inhibitory factor (MIF)
US7838542B2 (en) 2006-06-29 2010-11-23 Kinex Pharmaceuticals, Llc Bicyclic compositions and methods for modulating a kinase cascade
EP2330909B1 (fr) * 2008-08-12 2013-09-18 GlaxoSmithKline LLC Composés chimiques
EP2493313B1 (fr) 2009-10-29 2017-12-13 Genosco Inhibiteurs de kinases
ES2805031T3 (es) 2016-02-10 2021-02-10 Sumitomo Chemical Co Método de producción de 1-metilpirrolidin-3-ol

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994027989A1 (fr) * 1993-05-21 1994-12-08 Glaxo Group Limited Derives de carbazole a activite d'inhibition de 17,20-lyase
EP0721943A1 (fr) * 1993-09-30 1996-07-17 Yamanouchi Pharmaceutical Co. Ltd. Derive d'azole et composition pharmaceutique le contenant

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3642781A (en) * 1968-10-15 1972-02-15 Warner Lambert Co Substituted acrylic acids and process for their production
US4237133A (en) * 1977-11-14 1980-12-02 Pfizer Inc. 1,9-Dihydroxyoctahydrophenanthrenes
GB8417559D0 (en) * 1984-07-10 1984-08-15 Pfizer Ltd Anti-diarrhoeal agents
LU86022A1 (fr) * 1985-07-25 1987-02-04 Cird Derives aromatiques polycyliques,leur procede de preparation et leur application dans les domaines pharmaceutique et cosmetique
NZ221729A (en) * 1986-09-15 1989-07-27 Janssen Pharmaceutica Nv Imidazolyl methyl-substituted benzimidazole derivatives and pharmaceutical compositions
JP2852659B2 (ja) * 1988-03-03 1999-02-03 富山化学工業株式会社 ピペラジン誘導体およびその塩
JPH07121933B2 (ja) * 1988-03-28 1995-12-25 キッセイ薬品工業株式会社 ジヒドロベンゾフラノン誘導体
US5273977A (en) * 1990-11-05 1993-12-28 Warner-Lambert Company Substituted tetrahydropyridines and hydroxypiperidines as central nervous system agents
JP3157882B2 (ja) 1991-11-15 2001-04-16 帝国臓器製薬株式会社 新規なベンゾチオフエン誘導体
GB9220735D0 (en) * 1992-10-02 1992-11-18 British Tech Group Heterocyclic amines
JPH06293640A (ja) * 1993-02-15 1994-10-21 Shin Nippon Yakuhin Kk 肝疾患治療剤および１，３−ベンゾキサチオール誘導体
JPH06239856A (ja) * 1993-02-15 1994-08-30 Shin Nippon Yakuhin Kk １，３−ベンゾオキサチオール−２−チオン誘導体
JPH07173120A (ja) * 1993-10-08 1995-07-11 Banyu Pharmaceut Co Ltd 置換芳香族カルボン酸誘導体
TR199700625T1 (xx) 1995-01-10 1998-02-21 Smithkline Beecham S.P.A. Osteoporoz (kemik erimesi) tedavisinde yararl� olan indol t�revleri.
AU4547896A (en) * 1995-02-03 1996-08-21 Banyu Pharmaceutical Co., Ltd. 4-oxo-2-butenoic acid derivatives
AU7505196A (en) * 1995-11-07 1997-05-29 Banyu Pharmaceutical Co., Ltd. Cyclic amic acid derivatives
JP2000501700A (ja) 1995-12-06 2000-02-15 アストラ・フアーマシユウテイカルズ・リミテツド 化合物
US6017919A (en) * 1996-02-06 2000-01-25 Japan Tobacco Inc. Compounds and pharmaceutical use thereof
FR2746098B1 (fr) * 1996-03-14 1998-04-30 Composes propynyl biaromatiques
MY118876A (en) * 1996-03-29 2005-02-28 Tanabe Seiyaku Co Butadiene derivatives and process for preparing thereof
IL127668A0 (en) 1996-07-09 1999-10-28 Smithkline Beecham Spa Indole derivatives for the treatment of osteoporosis
US6005000A (en) * 1996-08-22 1999-12-21 Oxis International, Inc. 5,5-Disubstituted-3, 4-dihydroxy-2(5H)-furanones and methods of use therefor

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994027989A1 (fr) * 1993-05-21 1994-12-08 Glaxo Group Limited Derives de carbazole a activite d'inhibition de 17,20-lyase
EP0721943A1 (fr) * 1993-09-30 1996-07-17 Yamanouchi Pharmaceutical Co. Ltd. Derive d'azole et composition pharmaceutique le contenant

Also Published As

Publication number Publication date
CA2281598A1 (fr) 1998-08-27
AU6229698A (en) 1998-09-09
ATE231128T1 (de) 2003-02-15
DE69810760T2 (de) 2003-11-20
EP0974584A1 (fr) 2000-01-26
WO1998037070A1 (fr) 1998-08-27
CN1251577A (zh) 2000-04-26
US6420375B1 (en) 2002-07-16
DE69810760D1 (de) 2003-02-20
EP0974584B1 (fr) 2003-01-15

Similar Documents

Publication Publication Date Title
EP0974584A4 (fr) Composes a anneaux condenses, leur procede de production et leur utilisation
DE69532817D1 (de) Verwendung von pyrazole verbindungen zur behandlung von glomerulonephritis, krebs, atherosklerose oder restenose
ATE293102T1 (de) Naphthalene derivate ,ihre herstellung und verwendung
HU913626D0 (en) Process for the production of new aryl and heteroaryl-ethylene derivatives
EP1652847A3 (fr) Dérivés de quinoline et quinazoline pour le traitement des tumors
ES8504131A1 (es) Un procedimiento para la preparacion de 4-amino-6,7-dimetoxi quinoles.
NO972481L (no) Fremgangsmåte ved fremstilling av sildenafil
DE69831937D1 (de) Bicyclische protein-farnesyl-transferase inhibitoren
FI913640A (fi) Foerfarande foer framstaellning av nitriler.
ES8401031A1 (es) Una tetrahidroftalimida.
NO964095L (no) Nye hydroksypyridinoner
ES2165911T3 (es) Derivado de aminoestilbazol y farmaco.
MY109430A (en) Aryl-fused and hetaryl-fused-2, 4-diazepine and 2, 4-diazocine antiarrhythmic agents.
ES8801545A1 (es) Un procedimiento para la preparacion de compuestos aminoheterociclicos
ES8504731A1 (es) Un procedimiento para preparar antra 1,9-cd-7pirazol-6(2h)-onas
ATE265854T1 (de) Azasteroidverbindung zur behandlung oder vorbeugung von prostatakrebs
AU2178199A (en) Azetidinecarboxamide derivatives for the treatment of cns disorders
ES8705363A1 (es) Un procedimiento para preparar derivados de tetrahidronaftaleno
ES8506700A1 (es) Un procedimiento para preparar nuevas 5-aminometil-imidazol-1-il-1,3-dialquil-1h-pirazol-4-il-aroil-metanonas
DE69501810D1 (de) Verwendung von 5-Thia-1,4-Diazabicyclo [4.2.0] Octane-3,8-dioxo Verbindungen in der Antitumor-Therapie

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19990806

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RIC1 Information provided on ipc code assigned before grant

Free format text: 7C 07D 213/06 A, 7C 07D 233/56 B, 7C 07D 401/06 B, 7C 07D 405/06 B, 7C 07D 409/06 B, 7C 07D 249/08 B, 7A 61K 31/415 B, 7A 61K 31/44 B, 7C 07D 233/54 B, 7A 61K 31/41 B

A4 Supplementary search report drawn up and despatched

Effective date: 20000330

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 20001207

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

RIN1 Information on inventor provided before grant (corrected)

Inventor name: YAMAOKA, MASUO, SHOYAMA VILLA

Inventor name: KAKU, TOMOHIRO

Inventor name: ITOH, FUMIO

Inventor name: AONO, TETSUYA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20030115

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20030115

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20030115

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20030115

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20030115

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

Ref country code: CH

Ref legal event code: EP

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20030219

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20030219

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REF Corresponds to:

Ref document number: 69810760

Country of ref document: DE

Date of ref document: 20030220

Kind code of ref document: P

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20030228

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: A. BRAUN, BRAUN, HERITIER, ESCHMANN AG PATENTANWAE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20030415

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20030415

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20030415

NLV1 Nl: lapsed or annulled due to failure to fulfill the requirements of art. 29p and 29m of the patents act
PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20030730

ET Fr: translation filed
PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

26N No opposition filed

Effective date: 20031016

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20050208

Year of fee payment: 8

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20050216

Year of fee payment: 8

Ref country code: GB

Payment date: 20050216

Year of fee payment: 8

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20050217

Year of fee payment: 8

REG Reference to a national code

Ref country code: CH

Ref legal event code: PFA

Owner name: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Free format text: TAKEDA CHEMICAL INDUSTRIES, LTD.#1-1 DOSHOMACHI 4-CHOME, CHUO-KU#OSAKA-SHI, OSAKA 541-0045 (JP) -TRANSFER TO- TAKEDA PHARMACEUTICAL COMPANY LIMITED#1-1, DOSHOMACHI 4-CHOME CHUO-KU#OSAKA (JP)

REG Reference to a national code

Ref country code: FR

Ref legal event code: CD

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20060219

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20060228

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20060228

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20060228

Year of fee payment: 9

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20060901

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20060219

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20061031

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20060228

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20070219